Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017

March 2017 | 40 pages | ID: GDD46802793EN
Global Markets Direct

Abstracts

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape.

Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively.

Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Overview
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Companies Involved in Therapeutics Development
Adgero Biopharmaceuticals Holdings Inc
Galderma SA
Mayne Pharma Group Ltd
PellePharm Inc
Transgene SA
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Drug Profiles
itraconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patidegib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-1042 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trifarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Dormant Projects
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Discontinued Products
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Product Development Milestones
Featured News & Press Releases
Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome
Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial
Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial
Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment
May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2017
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Galderma SA, H1 2017
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Mayne Pharma Group Ltd, H1 2017
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by PellePharm Inc, H1 2017
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline by Transgene SA, H1 2017
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Dormant Projects, H1 2017
Gorlin Syndrome (Basal Cell Nevus Syndrome) - Discontinued Products, H1 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017